J Formos Med Assoc. 2018 May;117(5):381-403. doi: 10.1016/j.jfma.2017.09.007. Epub 2017 Oct 24.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC.
The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention.
The consensus statements were discussed, debated and got consensus in each expert team. And then the statements were sent to all of the experts for further discussion and refinement. Finally, all of the experts were invited to vote for the statements, including the level of evidence and recommendation.
With the development of the management consensus guideline, HCC patients could benefit from the optimal therapeutic modality.
肝细胞癌 (HCC) 是台湾癌症相关死亡的主要原因之一。为帮助临床医生管理 HCC 患者，台湾肝癌医学会和台湾胃肠病学会制定了 HCC 管理共识指南。
建议主要集中在 HCC 管理的九个重要问题上，包括监测、诊断、分期、手术、局部消融、经动脉化疗栓塞/经动脉放射栓塞/肝动脉灌注化疗、系统治疗、放疗和预防。
共识声明在每个专家小组中进行了讨论、辩论并达成共识。然后将声明发送给所有专家进一步讨论和完善。最后，邀请所有专家对声明进行投票，包括证据水平和建议。
随着管理共识指南的发展，HCC 患者将受益于最佳治疗方式。
